GeneDx Holdings A Aktie

GeneDx reports strong volume growth (up 32% year-to-date) and an earlier return to adjusted profitability, but confirms its 2026 revenue forecast of at least $475 million. Commercial insurance coverage for whole-genome sequencing rose to 88%, yet actual realized payments on insurance billings were only about 32%. Management sees the gap between volume and cash collections as the key operational challenge and is focused on improvements in the billing cycle, customer experience, product quality and capital discipline. The company expects material revenue effects from new reimbursement policies more likely in 2027 than at the end of 2026. » More on de.investing.com

Prosight Management disclosed a purchase of 468,463 shares of GeneDx Holdings, an estimated $42.7 million addition that now represents about 5.51% of its reportable AUM. GeneDx reported Q1 revenue up 17% to $102.3 million and testing volume up 34% to 27,488 tests, and management still expects at least 30% exome and genome volume growth and roughly 70% adjusted gross margins for the year. The company lowered its full-year revenue guidance to $475–490 million from $540–555 million, and its shares are down about 30% over the past year. Prosight’s purchase signals confidence in GeneDx’s growing genomic database and AI-driven diagnostics despite the revised outlook. » More on finance.yahoo.com

GeneDx reported Q1 2026 test volume of 27,488 exome/genome tests (+34% y/y), but revenue was $102.3m, below the expected $114m. The adjusted net loss was $8.2m, adjusted gross margin remained 69%, and cash and cash equivalents stood at $171.7m. The company cut its full-year guidance to $475–490m and expects an adjusted net loss of about $5m in Q2, while still planning for a positive adjusted full-year net income. As a countermeasure, GeneDx announced a four-point program to improve product mix, channel management, the revenue cycle and automation. » More on de.investing.com